Department of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA.
Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children, Sacramento, CA, 95817, USA.
Adv Biol (Weinh). 2022 Oct;6(10):e2200087. doi: 10.1002/adbi.202200087. Epub 2022 Jul 1.
Cardiovascular diseases (CVD) remain one of the leading causes of mortality worldwide. Despite recent advances in diagnosis and interventions, there is still a crucial need for new multifaceted therapeutics that can address the complicated pathophysiological mechanisms driving CVD. Extracellular vesicles (EVs) are nanovesicles that are secreted by all types of cells to transport molecular cargo and regulate intracellular communication. EVs represent a growing field of nanotheranostics that can be leveraged as diagnostic biomarkers for the early detection of CVD and as targeted drug delivery vesicles to promote cardiovascular repair and recovery. Though a promising tool for CVD therapy, the clinical application of EVs is limited by the inherent challenges in EV isolation, standardization, and delivery. Hence, this review will present the therapeutic potential of EVs and introduce bioengineering strategies that augment their natural functions in CVD.
心血管疾病(CVD)仍然是全球主要死因之一。尽管最近在诊断和干预方面取得了进展,但仍迫切需要新的多方面治疗方法,以解决导致 CVD 的复杂病理生理机制。细胞外囊泡(EVs)是由所有类型的细胞分泌的纳米囊泡,用于运输分子货物并调节细胞内通讯。EVs 是纳米治疗学的一个新兴领域,可以作为 CVD 早期检测的诊断生物标志物,以及作为靶向药物递送囊泡,促进心血管修复和恢复。尽管 EVs 是 CVD 治疗的一种很有前途的工具,但由于 EV 分离、标准化和递送方面固有的挑战,其临床应用受到限制。因此,本综述将介绍 EVs 的治疗潜力,并介绍增强其在 CVD 中天然功能的生物工程策略。
Adv Biol (Weinh). 2022-10
J Neuroimmune Pharmacol. 2020-9
Adv Healthc Mater. 2022-3
Nat Rev Cardiol. 2020-6-1
Adv Clin Chem. 2021
Stem Cell Res Ther. 2025-8-29
J Funct Biomater. 2023-2-19
Front Cardiovasc Med. 2021-12-9
Adv Nanobiomed Res. 2021-11
Adv Healthc Mater. 2022-3
Adv Clin Chem. 2021
Nat Nanotechnol. 2021-7
J Extracell Vesicles. 2021-6